Medindia

X

Medical Marijuana, Inc. Subsidiary, HempMeds® Brasil Highlights Vast International Media Coverage of Company Growth

Friday, January 27, 2017 Drug News J E 4
Advertisement

SAN DIEGO, Jan. 26, 2017 /PRNewswire/ --  Medical Marijuana, Inc. (OTC PINK: MJNA), the first publicly traded cannabis company in the United States, subsidiary, HempMeds Brasil™ today announced that it has recently received global coverage and recognition for the company's strides in the country of Brazil.

HempMeds Brasil™ is the first company to offer legal medicinal cannabis products to Brazil after receiving import approval to those suffering from specific medical conditions. The company's array of coverage features a variety of stories highlighting HempMeds Brasil™ growth, team expansion, and product success. 

Over the last year, the company has seen exponential growth. This was no more apparent than when the Brazilian government approved HempMeds Brasil™ products as a prescription medication for import into the country. In a historic step forward for the nation of Brazil, and the cannabis industry, HempMeds Brasil™  was permitted to provide Real Scientific Hemp Oil™ (RSHO™) under approval for medical indications. The groundbreaking announcement was reported on around the globe, and stood as a defining mark for HempMeds Brasil™. This decision came at the hands of Brazil's National Health Surveillance Agency, ANIVISA. As reported by Povo and Veja.com, the result of the monumental import agreement now permits any resident of Brazil who has a government-approved medical indication to gain access to RSHO Hemp Oil Products™.

"We have so much to be proud of and even more to look forward to," continued Dr. Titus. "The goal of our company is and always has been to put an end to the needless suffering of those around the world. We have set our sights on Brazil as a nation willing to challenge convention in order to set forth progress. Given the historic nature of our import agreement established through ANIVISA, and the success of RSHO-X™ in Brazil, we look brightly upon the future of HempMeds Brasil™ as a company intent on making a difference."

About HempMeds Brasil™HempMeds Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson's and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds Brasil is working on additional approvals for multiple indications.

About Medical Marijuana, Inc.Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSUREThese statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSUREMedical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

CONTACT:Public Relations Contact:Andrew HardChief Executive OfficerCMW MediaP. 888-829- 0070andrew.hard@cmwmedia.comwww.cmwmedia.com

 

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medical-marijuana-inc-subsidiary-hempmeds-brasil-highlights-vast-international-media-coverage-of-company-growth-300397142.html

SOURCE Medical Marijuana, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Candidate Biomarkers for Postmenopausal Osteoporos...
S
Global Market for Portable Ultrasound Bladder Scan...